Christopher Chen is a Cardiology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2485 High School Ave Ste 100
Concord, CA 945201816
Telephone
925-671-0610Provider last certified this registry record 3 Aug 2022.
Clinical trials
- Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study
Sponsor: National University Hospital, Singapore
Overall officialPhase 1Active, not recruitingNCT07210528 - Alzheimer's Disease THErapy With NEuroaid II
Sponsor: Moleac Pte Ltd.
Overall officialPhase 3Not, yet, recruitingNCT07191028 - MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits
Sponsor: Moleac Pte Ltd.
Overall officialPhase 2CompletedNCT05289947
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
39 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BIOTRONIK INC.Program year202531 payments
- Novartis Pharmaceuticals CorporationProgram year202525 payments
- Abbott LaboratoriesProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
81.3%Beta blocker18.5%Metoprolol Succinate42%Carvedilol38%Metoprolol Tartrate9%Atenolol6%Nebivolol Hcl2%Bisoprolol Fumarate1%Labetalol Hcl1%Propranolol Hcl1%Part D<11 patientsStatin17.5%Rosuvastatin Calcium48%Atorvastatin Calcium39%Simvastatin8%Pravastatin Sodium5%Lovastatin1%Part D<11 patients+ 17 more classes in this area
Blood & clotting
11%Factor Xa inhibitor7.7%Eliquis74%Xarelto26%Part D≥138 patientsP2Y12 inhibitor2.3%Clopidogrel90%Brilinta10%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
6.6%SGLT2 inhibitor3.2%Jardiance47%Farxiga47%Dapagliflozin6%Part D<11 patientsPotassium supplement2.1%Potassium Chloride90%Klor-Con 1010%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”